Inclusion Criteria:  People between 60-85 years old, willing to participate and comply with all the study evaluation and intervention procedures. With a CAIDE dementia Risk score ≥ 6  Below-than-expected cognitive performance in at least one of three brief cognitive tests:  Fototest score ≤ 35 Memory Alteration Test -T@M score ≤40 Cognitive complaints as compared with a previous subjective performance - defined by a Cognitive Change Index - self-report version score >=20 on the first 12 (episodic memory) items to assist with defining Subjective Cognitive Decline (SCD) (Risacher et al. 2017).  Exclusion Criteria:  Exclusion criteria are conditions that may affect the achievement of study objectives and procedures or clinical diagnoses that by themselves compromise participant's cognitive performance or compliance with study procedures. They include:  Inability to perform a neuropsychological evaluation or a cognitive stimulation program (sensory limitation, mental retardation, illiteracy) Barthel index < 90. Geriatric Depression Scale ≥ 9 Dementia or Moderate Cognitive impairment (MMSE < 20). Presence of any neurological, psychiatric or systemic disease that produce cognitive impairment or dementia including, but not limited to, Huntington's disease, multiple sclerosis, Parkinson's disease, Down syndrome, alcohol abuse or active drugs, or major psychiatric disorders including ongoing major depression, schizophrenia or bipolar or schizoaffective disorder. Unstable ischemic cardiopathy, uncontrolled heart arrhythmia, thromboembolic disease in the last year. Moderate cardiorespiratory insufficiency (including Class III or IV congestive heart failure, clinically significant aortic stenosis, cardiac arrest history, or uncontrolled angina). Currently receiving physical therapy or cardiopulmonary rehabilitation. Large vessel stroke in the past two years History of transient ischemia attack (TIA) or small vessel stroke in the last 6 months Any cerebrovascular accident with significant residual effects on cognition or functional autonomy. History within the last 2 years of treatment for primary or recurrent malignant disease, excluding non-melanoma skin cancers, resected cutaneous squamous cell carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or situ prostate cancer with normal prostate-specific antigen posttreatment Recent (< 3 months) bone fracture. History of hip fracture, joint replacement, or spinal surgery in the last 6 months Clinically significant abnormalities in laboratory blood tests as per judgment of the site Study Clinician Any conditions affecting safe engagement in the intervention in the judge of the study investigators.